Erratum to 'Opinion paper on the diagnosis and treatment of progressive familial intrahepatic cholestasis' [JHEP Reports 6 (2024) 100949]

Autor: Patrick McKiernan, Jesus Quintero Bernabeu, Muriel Girard, Giuseppe Indolfi, Eberhard Lurz, Palak Trivedi

Publikováno v: JHEP Reports, Vol 6, Iss 6, Pp 101058- (2024)

Externí odkaz: https://doaj.org/article/7bf129223b0e40f5adba9a87ae1b09f4

Interim results from an ongoing, open-label, single-arm trial of odevixibat in progressive familial intrahepatic cholestasis

Autor: Richard J. Thompson, Reha Artan, Ulrich Baumann, Pier Luigi Calvo, Piotr Czubkowski, Buket Dalgic, Lorenzo D’Antiga, Angelo Di Giorgio, Özlem Durmaz, Emmanuel Gonzalès, Tassos Grammatikopoulos, Girish Gupte, Winita Hardikar, Roderick H.J. Houwen, Binita M. Kamath, Saul J. Karpen, Florence Lacaille, Alain Lachaux, Elke Lainka, Kathleen M. Loomes, Cara L. Mack, Jan P. Mattsson, Patrick McKiernan, Quanhong Ni, Hasan Özen, Sanjay R. Rajwal, Bertrand Roquelaure, Eyal Shteyer, Etienne Sokal, Ronald J. Sokol, Nisreen Soufi, Ekkehard Sturm, Mary Elizabeth Tessier, Wendy L. van der Woerd, Henkjan J. Verkade, Jennifer M. Vittorio, Terese Wallefors, Natalie Warholic, Qifeng Yu, Patrick Horn, Lise Kjems

Publikováno v: JHEP Reports, Vol 5, Iss 8, Pp 100782- (2023)

Background & Aims: PEDFIC 2, an ongoing, open-label, 72-week study, evaluates odevixibat, an ileal bile acid transporter inhibitor, in patients with progressive familial intrahepatic cholestasis. Methods: PEDFIC 2 enrolled and dosed 69 patients acros

Externí odkaz: https://doaj.org/article/943aa785601b46a586443dc2851475ff

Variation in Alanine Aminotransferase in Children with Non-Alcoholic Fatty Liver Disease

Autor: Eduardo Castillo-Leon, Heather L. Morris, Cheryl Schoen, Jacob Bilhartz, Patrick McKiernan, Tamir Miloh, Sirish Palle, Mohammad Nasser Kabbany, Breda Munoz, Andrea R. Mospan, Bryan Rudolph, Stavra A. Xanthakos, Miriam B. Vos, TARGET-NASH Investigators

Publikováno v: Children, Vol 9, Iss 3, p 374 (2022)

Background: Pediatric non-alcoholic fatty liver disease (NAFLD) is a major public health concern. Aminotransferase (ALT) is frequently used for screening and monitoring, but few studies have reported typical patterns of ALT elevation in children. Met

Externí odkaz: https://doaj.org/article/0f083155b0ed468a8ca62e5e05569e87

Odevixibat treatment in progressive familial intrahepatic cholestasis

Autor: Richard J Thompson, Henrik Arnell, Reha Artan, Ulrich Baumann, Pier Luigi Calvo, Piotr Czubkowski, Buket Dalgic, Lorenzo D'Antiga, Özlem Durmaz, Björn Fischler, Emmanuel Gonzalès, Tassos Grammatikopoulos, Girish Gupte, Winita Hardikar, Roderick H J Houwen, Binita M Kamath, Saul J Karpen, Lise Kjems, Florence Lacaille, Alain Lachaux, Elke Lainka, Cara L Mack, Jan P Mattsson, Patrick McKiernan, Hasan Özen, Sanjay R Rajwal, Bertrand Roquelaure, Mohammad Shagrani, Eyal Shteyer, Nisreen Soufi, Ekkehard Sturm, Mary Elizabeth Tessier, Henkjan J Verkade, Patrick Horn

Publikováno v: The lancet. Gastroenterology & hepatology, 7(9), 830-842. HANLEY & BELFUS-ELSEVIER INC
Thompson, R J, Arnell, H, Artan, R, Baumann, U, Calvo, P L, Czubkowski, P, Dalgic, B, D'Antiga, L, Durmaz, Ö, Fischler, B, Gonzalès, E, Grammatikopoulos, T, Gupte, G, Hardikar, W, Houwen, R H J, Kamath, B M, Karpen, S J, Kjems, L, Lacaille, F, Lachaux, A, Lainka, E, Mack, C L, Mattsson, J P, McKiernan, P, Özen, H, Rajwal, S R, Roquelaure, B, Shagrani, M, Shteyer, E, Soufi, N, Sturm, E, Tessier, M E, Verkade, H J & Horn, P 2022, ' Odevixibat treatment in progressive familial intrahepatic cholestasis : a randomised, placebo-controlled, phase 3 trial ', The Lancet Gastroenterology & Hepatology . https://doi.org/10.1016/S2468-1253(22)00093-0

BACKGROUND: Progressive familial intrahepatic cholestasis (PFIC) is a group of inherited paediatric liver diseases resulting from mutations in genes that impact bile secretion. We aimed to evaluate the effects of odevixibat, an ileal bile acid transp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e8a1a56cdab28cb1e6e0e3bfd44955b
https://doi.org/10.1016/s2468-1253(22)00093-0

Validation of a Clinical Risk-based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort

Autor: Arun J. Sanyal, Breda Munoz, Kenneth Cusi, A. Sidney Barritt, Mark Muthiah, Andrea R. Mospan, K. Rajender Reddy, Roberto Firpi-Morell, Paul J. Thuluvath, Kalyan Ram Bhamidimarri, Michael W. Fried, Manal Abdelmalek, Humberto Aguilar, Aijaz Ahmed, Alina Allen, Sarah Barlow, Sid Barritt, David Bernstein, Kaylan Bhamidimarri, Liana Billings, Kyle Brown, Robert Brown, Karen Corbin, Andrew deLemos, Karan Emerick, Maged Adel Ghali, Zachary Henry, Whitney Jackson, Sujit Janardhan, Mohammad Kabbany, Nyingi Kemmer, David Koch, Justin Kupec, Charles Landis, Mary Katherine Lawrence, Cynthia Levy, Steven Lidofsky, Anna Lok, Velimir Luketic, Enrique Martinez, Craig McClain, Patrick McKiernan, Ellen Mitchell, Mazen Noureddin, Sirish Palle, Yen Pham, David Pound, Rajender Reddy, Fredric Regenstein, Mary Rinella, Fedja Rochling, Bryan Rudolph, Vinod Rustgi, Adnan Said, Niharika Samala, Souvik Sarkar, Kenneth Sherman, Mitchell Shiffman, Coleman Smith, Jawahar Taunk, Brent Tetri, Paul Thuluvath, Huy Trinh, Elizabeth Verna, Miriam Vos, L. Michael Weiss, Mark Wong, Kathleen Wyne, Stavra Xanthakos

Publikováno v: Clinical Gastroenterology and Hepatology.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1657a59c018b8901281c5247bc991d7e
https://doi.org/10.1016/j.cgh.2023.02.024